Vulfovich Michel, Rocha-Lima Caio
Sylvester Comprehensive Cancer Center/University of Miami School of Medicine, Miami, FL, USA.
Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002. doi: 10.1586/14737140.8.6.993.
Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement in survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.
晚期胰腺癌的治疗进展甚微。十多年来，吉西他滨一直是可接受的标准治疗药物。单药吉西他滨治疗晚期和转移性胰腺癌的疗效有限。在吉西他滨基础上加用其他化疗药物并未显著改善患者生存期。与单用吉西他滨相比，研究在吉西他滨基础上加用分子靶向药物（西妥昔单抗、贝伐单抗、法尼基转移酶抑制剂和金属蛋白酶抑制剂）的随机试验结果令人失望。最近有报道称，在吉西他滨基础上加用厄洛替尼可使中位生存期略有延长。本文综述了可能改变目前对这种具有挑战性疾病治疗中虚无主义态度的胰腺癌新型药物。
